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Drug-resistant Mycobacterium tuberculosis	 is	challenging	
elimination	of	tuberculosis	(TB).	We	evaluated	risk	factors	
for	TB	and	levels	of	second-line	drug	resistance	in	M. tu-
berculosis	 in	 patients	 in	 Europe	 with	 multidrug-resistant	
(MDR)	TB.	A	total	of	380	patients	with	MDR	TB	and	376	
patients	with	non–MDR	TB	were	enrolled	at	23	centers	in	
16	countries	in	Europe	during	2010–2011.	A	total	of	52.4%	
of	MDR	TB	patients	had	never	been	treated	for	TB,	which	
suggests	primary	transmission	of	MDR	M. tuberculosis.	At	
initiation	of	treatment	for	MDR	TB,	59.7%	of	M. tuberculo-
sis	 strains	 tested	were	 resistant	 to	 pyrazinamide,	 51.1%	
were	resistant	to	≥1	second-line	drug,	26.6%	were	resis-
tant	to	second-line	injectable	drugs,	17.6%	were	resistant	
to	 fluoroquinolones,	 and	6.8%	were	extensively	 drug	 re-
sistant.	Previous	 treatment	 for	TB	was	 the	strongest	 risk	
factor	 for	 MDR	 TB.	 High	 levels	 of	 primary	 transmission	
and	advanced	resistance	to	second-line	drugs	character-
ize	MDR	TB	cases	in	Europe.
Emergence of drug-resistant tuberculosis (TB) threat-ens the goal of TB elimination (1). Multidrug-resistant 
(MDR) TB is defined by in vitro resistance of Mycobac-
terium tuberculosis to at least both of the 2 most effective 
drugs for treatment (rifampin and isoniazid). Extensively 
drug-resistant TB (XDR TB) is defined as MDR TB plus 
in vitro resistance to at least 1 second-line injectable drug 
(amikacin, capreomycin, or kanamycin) plus resistance to 
any of the fluoroquinolones (e.g., ofloxacin, levofloxacin, 
or moxifloxacin) (2). In the World Health Organization 
(WHO) European Region, the estimated incidence of pa-
tients with MDR TB differs markedly: 1.6 cases/100,000 
persons in the 29 European Union/European Economic 
Area countries and 16.8 cases/100,000 persons in the 24 
other countries of the region in 2012 (online Technical Ap-
pendix Table 1, http://wwwnc.cdc.gov/EID/article/21/3/14-
1343-Techapp1.pdf) (3). The actual number of patients with 
Multidrug-Resistant Tuberculosis  
in Europe, 2010–2011
Gunar Günther, Frank van Leth, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang,  
Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, 
Raquel Duarte, Gina Gualano, Heinke Kunst, Wiel de Lange, Vaira Leimane, Cecile Magis-Escurra,  
Anne-Marie McLaughlin, Inge Muylle, Veronika Polcová, Emanuele Pontali, Christina Popa,  
Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi,  
Piret Viiklepp, Christoph Lange, TBNET1
1Additional	contributors	from	TBNET	are	listed	at	the	end	of	 
this	article.
Author	affiliations:	University	of	Namibia	School	of	Medicine,	
Windhoek,	Namibia	(G.	Günther,	C.	Lange);	German	Center	for	
Infection	Research,	Research	Center	Borstel,	Borstel,	Germany	
(G.	Günther,	C.	Lange);	University	of	Amsterdam,	Amsterdam,	
the	Netherlands	(F.	van	Leth);	Institute	of	Phthisiopneumology,	
Chisinau,	Moldova	(S.	Alexandru,	A.	Ciubanu,	V.	Crudu);	Hospital	
Universitari	Vall	d’Hebron,	Barcelona,	Spain	(N.	Altet);	Jordi	Gol	
University,	Barcelona	(N.	Altet);	Asklepios	Klinik	Gauting,	Gauting,	
Germany	(K.	Avsar);	Statens	Serum	Institut,	Copenhagen,	 
Denmark	(D.	Bang);	Herlev	Hospital,	Herlev,	Denmark	(D.	Bang);	
Balti	Municipal	Hospital,	Balti,	Moldova	(R.	Barbuta);	Homerton	
University	Hospital,	London,	UK	(G.	Bothamley);	National	TB	
Reference	Laboratory,	Chisinau,	Moldova	(V.	Crudu);	Tartu	 
University	Lung	Hospital,	Tartu,	Estonia	(M.	Danilovits);	University	
of	Warwick,	Coventry,	UK	(M.	Dedicoat);	Heart	of	England	 
Foundation	Trust,	Birmingham,	UK	(M.	Dedicoat,	H.	Kunst);	
Vila	Nova	de	Gaia/Espinho	Medical	School,	Vila	Nova	de	Gaia,	
Portugal	(R.	Duarte);	Porto	University,	Porto,	Portugal	(R.	Duarte);	
National	Institute	for	Infectious	Diseases	L.	Spallanzani,	Rome,	
Italy	(G.	Gualano);	Queen	Mary	University,	London	(H.	Kunst);	
University	Medical	Center	Groningen,	Groningen,	the	Netherlands	
(W.	de	Lange);	Riga	East	University	Hospital,	Riga,	Latvia	 
(V.	Leimane);	Radboud	University	Medical	Centre,	Nijmegen/
Groesbeek,	the	Netherlands	(C.	Magis-Escurra);	St.	James’s	 
Hospital,	Dublin,	Ireland	(A.-M.	McLaughlin);	University	Medical	 
Center	St.	Pieter,	Brussels,	Belgium	(I.	Muylle);	Thomayer	 
University	Hospital,	Prague,	Czech	Republic	(V.	Polcavá);	Galliera	
Hospital,	Genoa,	Italy	(E.	Pontali);	Marius-Nasta-Institut,	 
Bucharest,	Romania	(C.	Popa,	V.	Spinu);	Otto	Wagner	Hospital,	
Vienna,	Austria	(R.	Rumetshofer);	Republican	Research	and	 
Practical	Centre	for	Pulmonology	and	Tuberculosis,	Minsk,	 
Belarus	(A.	Skrahina,	V.	Solodovnikova);	Azienda	Ospedaliera	
della	Valtellina	e	della	Valchiavenna	E.	Morelli	Reference	Hospital	
for	MDR	and	HIV-TB,	Sondalo,	Italy	(S.	Tiberi);	Barts	Health	 
National	Health	Service	Trust,	London	(S.	Tiberi);	National	
Institute	for	Health	Development,	Tallinn,	Estonia	(P.	Viiklepp);	
Karolinska	Institute,	Stockholm,	Sweden	(C.	Lange)
DOI:	http://dx.doi.org/10.3201/eid2103.141343
RESEARCH
410	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	21,	No.	3,	March	2015
MDR TB living in this region may be much higher because 
a substantial proportion of patients are never screened for 
drug-resistant TB before starting treatment, partly because 
of a lack of diagnostic capacity (3).
MDR TB is associated with poor treatment outcomes 
(1,2,4). The proportion of treatment success in patients 
with MDR TB was only 54% in an individual patient data 
metaanalysis of >9,000 patients from 32 observational 
studies (5). Results from this cohort showed that additional 
resistance to fluoroquinolones in patients with MDR TB 
reduced treatment success to 48%; patients with XDR TB 
were treated successfully in 40% of cases (6), which ap-
proached treatment outcomes similar to those of the pre–
antimicrobial drug era (4). A recent surveillance report 
from the EU reported 32.2% treatment success for MDR 
TB and 19.1% treatment success for XDR TB (7).
Detailed information about characteristics, manage-
ment, and outcomes of patients with MDR TB in Europe 
is scarce but essential to inform health policy makers and 
optimize disease management (8). We compared baseline 
characteristics and risk factors for patients with MDR TB, 
as well as availability and results of drug susceptibility test-
ing (DST) for second-line drugs for treatment of TB, in a 
cohort of patients from 16 countries in Europe with low, 
intermediate, and high incidence of TB, who had started 
first-line or second-line TB treatment.
Methods
Participating Sites
TBNET is a European consortium for clinical research in 
the field of TB (9). This study was conducted at 23 TBNET 
sites in 16 countries in Europe: 2 with a high (>100 cas-
es/100,000 persons) incidence of TB, 4 with an intermediate 
(20–100 cases/100,000 persons) incidence, and 10 with a 
low (<20 cases/100,000 persons) incidence (Figure). Strati-
fication was based on WHO/European Centre for Disease 
Prevention and Control estimates of TB incidence during 
the study period (2010–2011) (10). The number of study 
participants per country is shown in online Technical Ap-
pendix Table 1.
Study Population
After informed consent was obtained, patients starting 
treatment for a new episode of culture-confirmed TB with 
resistance to at least rifampin and isoniazid (MDR TB co-
hort) were eligible for enrollment. Patients were included 
prospectively by using consecutive inclusion during Janu-
ary 2010–December 2011 at each site. In Belarus, Latvia, 
Moldova, and Romania, additional enrollment was stopped 
when a preagreed number of patients were enrolled to 
avoid overrepresentation of patients from these countries 
in the cohort.
For each MDR TB patient, 1 patient with non–MDR 
TB (pan drug–susceptible, monoresistant, or polydrug-
resistant TB [11]) was enrolled at each center at the time 
of enrollment of the MDR TB patient: these additional pa-
tients were denoted as controls. Controls were selected on 
the basis of DST results that identified non–MDR TB, and 
that were obtained at the closest date before enrollment of 
an MDR TB patient at the same site.
Because of this selection process, a limited number 
of patients (41, 5.4%) started treatment before the study 
began in January 2010, but none started treatment before 
Figure.	TBNET	study	sites	in	
the	Pan	European	network	for	
study	and	clinical	management	
of	drug-resistant	tuberculosis	
(TBPAN-NET)	project.	
Stratification	is	based	on	the	
incidence	of	tuberculosis	(TB)	
reported	during	2010–2011,	
which	matched	the	inclusion	
period	of	the	study.	Data	for	
2011	were	obtained	from	the	
European Centre for Disease 
Control	and	Prevention	
(10).	Low	TB	incidence,	<20	
cases/100,000	persons;	
intermediate	TB	incidence,	 
20–100	cases/100,000	
persons;	high	TB	incidence,	
>100	cases/100,000	persons.
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January 2007. However, we maintained consecutive inclu-
sion for MDR TB patients. This feature ensured an accept-
able sample size for countries with a low incidence of TB 
during the inclusion period.
Data Collection
Data collection used an electronic case record form de-
signed in Open Clinica (http://www.openclinica.com). A 
paper version of this form was used in Moldova, Romania, 
Estonia, and Belarus, where internet access was not always 
available. All investigators were initially trained onsite, 
and continuous training was ensured through annual inves-
tigator meetings, regular site visits, and newsletters.
Laboratory Testing
Routine data were obtained from local laboratory reports 
for sputum smear microscopy, sputum culture, and DST 
for first-line and second-line drugs and, when available, 
M. tuberculosis–specific nucleic acid amplification tests. 
All laboratories at study sites were subjected to quality 
control through the WHO Supranational Reference Labo-
ratory Network.
Study Outcome
We analyzed characteristics of the cohort at the time of en-
rollment. We also assessed factors associated with MDR 
TB in a cross-sectional approach.
Data Management
Data management included regular data checks on key 
variables for missing data and inconsistencies. The study 
coordinator, a study monitor, and a trained study nurse per-
formed routinely manual plausibility checks and clarified 
inconsistencies with the investigators.
Statistical Analysis
Descriptive statistics are reported as frequencies or medians, 
where appropriate. Risk factor analysis was performed by 
using univariable and multivariable logistic regression. We 
used robust SEs to adjust for clustering by country. All vari-
ables with <20% missing data were assessed for inclusion in 
the models. Missing data for included variables were coded 
as separate categories to prevent listwise deletion of obser-
vations. Age was dichotomized at 45 years to align with 
values in a previous study (12). The variables age and sex 
were purposefully included in the multivariable analysis in 
which other variables were included on the basis of the Wald 
statistic (<0.1) and the change in the pseudo R2 (>10%) be-
cause a robust SE precludes formal use of the log-likelihood 
ratio test. In a sensitivity analysis, we repeated multivariable 
logistic regression with the inclusion of a sampling weight 
for the MDR TB patients (inverse of the sampling fraction 
with expected number of MDR TB patients in the country 
as denominator) (online Technical Appendix Table 5). Non–
MDR TB patients were given a weight of 1. The weighted 
analyses assessed the potential effect of unbalanced contri-
bution of countries in the cohort. Goodness-of-fit was as-
sessed by using the F-adjusted mean residual test.
Drug resistance was expressed as the proportion of iso-
lates tested and the proportion of isolates that were resis-
tant. Corresponding frequencies when applying sampling 
weights and analysis by a complex survey approach (13,14) 
are shown in online Technical Appendix Table 4.
Ethics
Patient information and consent forms were translated into 
local languages when needed. The study was approved by 
the Ethics Committee of the University of Lübeck (Lübeck, 
Germany). The study protocol was approved by the local 
ethics committee at all participating centers. Written in-
formed consent was obtained from all patients according 
to site-specific regulations. Data were collected pseudony-
mously and stored on a secured server.
Results
Cohort Characteristics
The cohort consisted of 380 MDR TB patients and 376 non–
MDR TB controls. Descriptive characteristics of the MDR 
TB cohort are shown in Table 1 (http://wwwnc.cdc.gov/EID/
article/21/3/14-1343-T1.htm) and those for the non–MDR 
TB cohort in online Technical Appendix Table 2. Both 
groups had predominantly male patients. The median age 
was 36 years (interquartile range 27–47 years) for the MDR 
TB patients and 41 years (interquartile range 31–54 years) 
for the controls. The proportion of foreign-born patients with 
MDR TB in countries of low, intermediate, and high TB inci-
dence was 85.4%, 5.8% and 0.5%, respectively. Similar pro-
portions were observed in controls (56.3%, 5.7% and 2.1%, 
respectively). Of 94 foreign-born patients, 60 (64%) were 
from countries of the European region of WHO, 17 (18%) 
from Russia, 18 (19%) from Southeast Asia, 11 (12%) from 
sub-Saharan Africa, 1 (1%) from North Africa, and 4 (4%) 
from South America. Smoking was common in both groups 
(50.5% for MDR TB patients and 41.5% for controls).
HIV infection and diabetes mellitus were infrequently 
observed: 6.6% in MDR TB patients and 4.3% in controls 
for HIV, and 4.2% in MDR TB patients and 5.3% in con-
trols for diabetes mellitus. The percentage of patients with 
MDR TB whose episode of active TB was their first was 
52.4% (59.2%, 74.4%, and 38.7% in countries with low, 
intermediate, and high TB incidence, respectively).
Drug Resistance Profiles
Among 380 patients with MDR TB, second-line M. tu-
berculosis DST profiles were available for 356 patients. 
MDR	TB,	Europe,	2010–2011
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Reasons for unavailable baseline DST results were 1) an 
initial diagnosis of MDR TB at a peripheral hospital and 
subsequent patient transfer to a central hospital where M. 
tuberculosis could not be grown in culture (n = 6); 2) con-
tamination of cultures (n = 12); 3) insufficient growth in 
cultures (n = 4); 4) patient death between the first and 
second cultures (n = 1), and 5) unknown reason (n = 1). 
Among patients with MDR TB, 6.8% of cases fulfilled 
the definition of XDR TB. Drug resistance profiles for 
first-line and second-line drugs other than rifampin and 
isoniazid are shown in Table 2 for the MDR TB cohort, 
in online Appendix Table 3 for the MDR TB cohort 
compared with the non–MDR TB cohort, and in online 
Technical Appendix Table 4 for the MDR TB cohort by 
weighted analysis.
DST for pyrazinamide and ethambutol was performed 
for 45.0% (177/380) and 97.6% (371/380) of strains from 
MDR TB patients and controls, respectively. Testing was 
performed for 94.7% (360/380) of strains for resistance to 
any second-line drug, 93.7% (356/380) for any second-
line injectable drug, 92.6% (352/380) for any fluoroqui-
nolone, and 93.2% (356/380) for ethionamide/prothion-
amide. Strains from MDR TB patients showed additional 
resistance to pyrazinamide (59.7%, 105/177), ethambutol 
(59.3%, 220/371), ≥1 second-line injectable drug (26.1%, 
93/356), ≥1 fluoroquinolone (17.6%, 62/352), and 
ethionamide/prothionamide (31.3%, 119/354) (Table 2). 
The weighted analysis showed higher proportions of re-
sistance to all drugs, except capreomycin, moxifloxacin, 
and ethionamide/prothionamide (online Technical Ap-
pendix Table 4).
Risk Factors for MDR TB
Risk factors for TB were compared between patients 
with MDR TB and controls. Previous treatment for TB 
(odds ratio 10.7, 95% CI 7.3–15.6) and age <45 years 
(OR 1.90, 95% CI 1.23–2.93) were identified as indepen-
dent risk factors for MDR TB by multivariable analysis 
(Table 3). There was also a moderate association for sex 
and current homelessness with MDR TB by weighted 
analysis (online Technical Appendix Table 5). No as-
sociation was found between MDR TB and abnormal 
body mass index (<18 or >25), employment status, birth 
in a foreign country, history of imprisonment, injectable 
drug use, co-infection with HIV, or diabetes. The role 
of TB contact was not evaluated because data were not 
sufficiently robust because of a high percentage of un-
known/unreliable results for self-reporting. Weighted 
analyses showed similar results with only minor differ-
ences in effect size. 
 
Table 2. Drug	resistance	profiles	for	first-line	and	second-line	drugs	used	for	treatment	of	multidrug-resistant	tuberculosis	in	TBNET	
study	in	Europe,	2010–2011* 
Drug† 
Incidence	of	TB	in	region All	MDR	TB	patients,	 
n	=	380 Low,	n	=	103† 
 
Intermediate	n	=	86‡ 
 
High	n	=	191§ 
Tested Resistant Tested Resistant Tested Resistant Tested Resistant 
First-line           
 Pyrazinamide 97	(94.2) 52	(53.6)  70	(81.4) 49	(71.0)  10	(5.2) 4	(40.0) 177	(45.0) 105	(59.7) 
 Ethambutol 99	(96.1) 50	(50.5)  85	(98.9) 55	(64.7)  187	(97.9) 115	(61.5) 371	(97.6) 220	(59.3) 
 Streptomycin 93	(90.3) 78	(83.9)  85	(98.9) 82	(96.5)  187	(97.9) 171	(91.4) 365	(96.1) 331	(90.7) 
1	non–first	line 101	(97.1) 66	(65.4)  86	(100) 64	(74.4)  173	(86.4) 64	(37.0) 360	(94.7) 194	(51.1) 
Class	II           
 Amikacin 95	(92.2) 17	(17.9)  85	(98.8) 25	(29.4)  1	(0.5) 0 181	(47.6) 42	(23.2) 
 Kanamycin 39	(37.9) 8	(20.5)  79	(91.9) 37	(46.8)  170	(89.0) 23	(13.5) 288	(75.8) 68	(23.6) 
 Capreomycin 88	(85.4) 15	(17.0)  84	(97.7) 26	(31.0)  94	(49.2) 4	(4.3) 266	(71.1) 45	(16.9) 
 1	second-line	inj. 100	(97.1) 24	(24.0)  86	(100) 42	(48.8)  170	(89.0) 27	(15.9) 356	(93.7) 93	(26.1) 
Class	III           
 Ofloxacin 69	(67.0) 16	(23.2)  86	(100) 26	(30.2)  169	(88.5) 14	(8.3) 324	(85.3) 56	(17.3) 
 Levofloxacin 16	(15.5) 1	(6.2)  7	(8.1) 1	(14.3)  10	(5.2) 2	(20.0) 32	(8.4) 4	(12.5) 
 Moxiflocacin 61	(59.2) 14	(23.0)  12	(14.0) 3	(25.0)  0  73	(19.2) 17	(23.3) 
 1	fluoroquinolone 96	(96.2) 21	(21.9)  86	(100) 26	(30.2)  170	(89.0) 15	(8.8) 352	(92.6) 62	(17.6) 
Class	IV           
 ETO/PTO 98	(95.1) 47	(48.0)  86	(100) 36	(41.9)  170	(89.0) 36	(21.2) 354	(93.2) 119	(31.3) 
 PAS 54	(52.4) 10	(18.5)  68	(79.1) 10	(14.7)  175	(91.6) 2	(1.1) 295	(77.6) 22	(7.5) 
 DCS/TRD 53	(51.5) 6	(11.3)  69	(80.2) 13	(18.8)  100	(52.4) 5	(5.0) 220	(57.9) 23	(10.6) 
Class	V           
 Linezolid 62	(60.2) 2	(3.2)  6	(7.0) 0  1	(0.5) 0 69	(18.2) 2	(2.9) 
 Imipenem 0 0  0 0  0 0 0 0 
 Meropenem 1	(1.0) 1	(100)  0 0  0 0 1	(0.3) 1	(100) 
 AMX/CLV 0 0  0 0  0 0 0 0 
 Clarithromycin 17	(16.5) 3	(17.7)  0 0  0 0 17	(4.5) 3	(17.6) 
*Values	are	no.	(%)	samples.	Unweighted	analysis	was	used.	TB,	tuberculosis;	MDR	TB,	multidrug-resistant	tuberculosis;	inj,	injectable;	ETO/PTO,	
ethionamide/prothionamide;	PAS,	para-aminosalicylic	acid;	DCS/TRD,	cycloserine/terizidone;	AMX/CLV,	amoxicillin/clavulanic	acid. 
†Austria,	Belgium,	Czech	Republic,	Denmark,	Germany,	Great	Britain,	Ireland,	Netherlands,	Italy,	and	Spain. 
‡Belarus,	Estonia,	Latvia,	and	Portugal. 
§Moldova	and	Romania. 
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Discussion
We studied a multicenter cohort of patients with MDR TB 
at 23 referral centers across Europe and found high rates of 
drug resistance to second-line drugs for treatment of TB in 
circulating M. tuberculosis strains, and limited availability 
of second-line drug resistance testing in several countries 
with a high incidence of TB. Furthermore, we found evi-
dence of ongoing transmission of MDR strains of M. tuber-
culosis in eastern Europe: 52.4% of patients with MDR TB 
were experiencing their first episode of TB. In countries in 
western Europe with a low incidence of TB, MDR TB is 
predominantly a disease of immigrants (15), which reflects 
the epidemiology of MDR TB in the country of origin. Only 
a few (8.9%) MDR TB patients were born outside the Eu-
ropean region of WHO. Thus, interventions for the control 
of MDR TB should be specific for countries with high inci-
dence of MDR TB, especially in eastern Europe (16).
Mathematical and epidemiologic models indicate that 
early diagnosis, effective treatment, and improved access 
to laboratory infrastructure could have a strong effect on 
the incidence of MDR TB in high-prevalence regions (17). 
However, few of such programmatic requirements are met 
at many sites in Europe at the present time (18).
Possible active transmission of strains causing MDR 
TB, as reflected by the large proportion of patients never 
having received TB treatment before in this European co-
hort, is consistent with recently reported data and deserves 
attention. A drug resistance survey conducted in Belarus in 
2011 showed that 32.3% of new TB infections and 75.6% 
of previously treated TB infections had an MDR strain of 
 
Table 3. Risk	factors	for	multidrug-resistant tuberculosis	in	patients in TBNET	study	in	Europe,	2010–2011* 
Factor 
Non–MDR	TB,	
n	=	376 
MDR	TB,	
n	=	380 
Univariable	analyisis 
 
Multivariable	analysis 
OR	(95%	CI) p	value OR	(95%	CI) p	value 
Sex        
 F 111 141 1 NA  1 NA 
 M 265 239 0.71	(0.52–0.97) 0.031  0.78	(0.53–1.14) 0.195 
Age,	y        
 <45 212 258 1.73	(1.16–2.58) 0.007  1.90	(1.23–2.93) 0.004 
 45 155 109 1 NA  1 NA 
 Unknown 4 10 NA NA  NA NA 
Body	mass	index        
 <18 31 48 1.64	(0.94–2.85) 0.082  NA NA 
 18–<25 276 261 1 NA  NA NA 
 25 38 49 1.36	(0.65–2.87) 0.414  NA NA 
Currently	employed        
 Yes 144 144 1 NA  NA NA 
 No 211 222 1.03	(0.71–1.49) 0.886  NA NA 
 Unknown 16 14 NA NA  NA NA 
Foreign	born        
 Yes 63 94 1.63	(1.12–2.38) 0.011  1.52	(0.89–2.61) 0.120 
 No 313 286 1 NA  1 NA 
Imprisonment	before	current	diagnosis        
 Yes 15 30 2.05	(0.75–5.66) 0.164  1.27	(0.82–1.97) 0.280 
 No 345 336 1 NA  1 NA 
 Unknown 16 14 NA NA  NA NA 
Current	homelessness        
 Yes 21 16 0.73	(0.43–1.24) 0.248  NA NA 
 No 346 359 1 NA  NA NA 
 Unknown 9 5 NA NA  NA NA 
Injectable	drug	user        
 Yes 13 24 1.87	(0.92–3.83) 0.084  1.32	(0.54–3.21) 0.541 
 No 332 327 1 NA  1 NA 
 Unknown 31 29 NA NA  NA NA 
HIV	infected        
 Yes 16 25 1.57	(0.86–2.87) 0.146  1.78	(0.81–3.89) 0.151 
 No 320 345 1 NA  1 NA 
 Not	tested 36 9 NA NA  NA NA 
 Unknown 4 1 NA NA  NA NA 
Diabetes        
 Yes 20 16 0.80	(0.32–1.98) 0.622  NA NA 
 No 354 356 1 NA  NA NA 
 Unknown 2 8 NA NA  NA NA 
Previous	TB	treatment        
 Yes 33 133 9.49	(7.05–12.76) <0.001  10.71	(7.33–15.63) <0.001 
 No 339 244 1 NA  1 NA 
 Unknown 4 3 NA NA  NA NA 
*MDR	TB,	multidrug-resistant	tuberculosis;	OR,	odds	ratio;	NA,	not	applicable. 
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M. tuberculosis (19). In Moldova, for which adequate sur-
veillance data are available, 23.7% of new TB cases in-
volve an MDR strain (3). A recent report of surveillance 
data in countries with >700 estimated MDR TB cases per 
year indicated that more than half of the reported pulmo-
nary MDR TB cases were new cases (20).
More than 90% of strains from MDR TB patients had 
undergone DST for ≥1 second-line injectable drug and flu-
oroquinolone.  The role of ethambutol and pyrazinamide 
for treatment of MDR TB is unclear. In our cohort, 97.6% 
and 45.0% of MDR TB strains were tested for resistance 
to ethambutol and pyrazinamide, respectively. In countries 
with a high incidence of TB, only 5.2% of MDR TB cases 
were tested for pyrazinamide resistance because of limited 
availability of liquid culture methods and special pH media 
requirements for pyrazinamide DST. Less than half of the 
strains tested were susceptible to these drugs. Currently, the 
mechanism of action of pyrazinamide in combination ther-
apy and the relevance of in vitro DST for pyrazinamide are 
uncertain. Findings from this study raise questions about a 
universal recommendation to treat MDR TB with pyrazin-
amide throughout the entire course of treatment (21).
In our study cohort, 1 of 3 M. tuberculosis strains with 
resistance to at least rifampin and isoniazid were also resis-
tant to protionamide/ethionamide, 1 of 4 were resistant to 
any second-line injectable drug, and 1 of 5 were resistant 
to a fluoroquinolone. Of all MDR TB cases, 6.8% fulfilled 
the definition of XDR TB. Surveillance data from the Euro-
pean Centre for Disease Prevention and Control indicated 
that 9.1% of cases of XDR TB in patients with MDR TB 
underwent second-line DST. Given the high proportion of 
strains that received a second-line DST, it is unlikely that 
these percentages are overstated because of preferred test-
ing of patients at high risk for acquiring TB.
Our results are consistent with those from the Preserv-
ing Effective TB Treatment Study (PETTS) (22), which in-
vestigated second-line drug resistance in strains from 1,278 
patients in 8 countries, including Latvia and Estonia, which 
were countries with study sites in this cohort. The main 
difference between PETTS study and ours was a high fre-
quency of M. tuberculosis resistance to prothionamide/ethi-
onamide in our cohort, which reflected the relatively higher 
frequency of treatment with this drug combination in eastern 
Europe than in other parts of the world (23). Recently pub-
lished data from the PETTS study showed an increased risk 
of acquiring resistance to second-line drugs during treatment 
and increased baseline resistance (24). Increased resistance 
to second-line drugs is associated with higher proportions of 
treatment failures (6). It can be assumed, if one considers the 
findings from the PETTS study, that many of the patients in 
our cohort are at high risk for treatment failure.
Of particular concern is resistance to fluoroquinolones 
because these drugs are the core of new treatment regimens 
(25,26), including regimens for patients with drug-sus-
ceptible strains of M. tuberculosis (26). In our study, the 
capacity to perform DST for later-generation fluoroquino-
lones (levofloxacin and moxifloxacin) was only present for 
19.2% of strains for levofloxacin and 8.4% of strains for 
moxifloxacin. Later generations of fluoroquinolones may 
still be effective for treatment of MDR TB in some patients 
when drug resistance to ofloxacin is documented (27). The 
capacity to perform DST for later generations of fluoroqui-
nolones needs to be improved in the region.
Multivariable analysis showed that previous TB treat-
ment and patient age <45 years showed an association with 
MDR TB (male sex and current homelessness showed an 
association in a weighted model). However, none of the 
other traditional risk factors for drug-resistant TB, such as 
HIV infection or birth in a foreign country (12), showed 
this association. Although  previous treatment for TB and 
contact with persons infected with drug-resistant strains 
have been reported as strong risk factors for MDR TB, the 
role of HIV infection, young age, sex, and previous impris-
onment are less clear (12,28). The high proportion of new 
cases and the lack of association of other traditional risk 
factors with drug-resistant TB suggest an increased role of 
ongoing transmission in the community outside established 
risk groups for becoming infected with drug-resistant 
strains of M. tuberculosis (19,20,29).
Our study has several major limitations. First, baseline 
data were obtained from an observational cohort study and 
were not derived from routine surveillance. Only 14 of 28 
countries from the European Union and 2 countries outside 
the European Union were represented in the study. Site se-
lection was based on voluntary participation in the study 
and being a center for the management of MDR TB. Be-
cause a high number of patients in Europe are being treated 
outside such centers, the generalizability of data might be 
limited. However, the included centers adhered to national 
policies regarding diagnosis and treatment of MDR TB 
patients and therefore reflect current practice. To provide 
a better estimation of representativeness of data for the 
situation in Europe, we additionally performed weighted 
analyses based on the sampling fraction and the expected 
number of reported MDR TB patients in the countries from 
which patients were recruited (online Technical Appen-
dix). Results suggest that frequencies of drug resistance to 
second-line drugs might be underestimated by our analysis.
Second, some data collected were self-reported by 
patients and are prone to information bias. This limitation 
particularly applies to information on previous TB treat-
ment in foreign-born patients, who might fear stigmatiza-
tion in the country where treatment was provided.
Third, DST was performed at laboratories that used 
external quality control practices. However, quality con-
trol for testing of second-line drugs varies among sites and 
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respective laboratories (30). Incompleteness of DST data 
for second-line drugs demonstrates the situation with which 
clinicians are confronted in making their management deci-
sions and shows the need for scale up in laboratory testing, 
even in MDR TB reference centers in Europe.
Despite these limitations, our study identified 3 ma-
jor concerns regarding TB in Europe. First, transmission of 
MDR strains of M. tuberculosis is ongoing. Second, diag-
nostic capacity is poor, especially for DST. Third, levels of 
resistance to second-line TB drugs are high. These factors 
must be addressed in any TB surveillance and control pro-
grams that are implemented.
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